# Krystal Biotech, Inc.: financial statements, quarterly

KRYS · Nasdaq · CIK 1711279 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/krys.md) · [Financials](/companies/krys/financials.md) · [Filings](/companies/krys/filings.md) · [Insiders](/companies/krys/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/krys/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [8.6](/filings/0001711279-24-000056.md) | [42.1 d](/filings/0001711279-26-000016.md) | [45.3](/filings/0001711279-25-000044.md) | [70.3](/filings/0001711279-25-000077.md) | [83.8](/filings/0001711279-25-000087.md) | [91.1 d](/filings/0001711279-26-000016.md) | [88.2](/filings/0001711279-26-000043.md) | [96.0](/filings/0001711279-26-000057.md) | [97.8](/filings/0001711279-25-000087.md) | [107 d](/filings/0001711279-26-000016.md) | [116](/filings/0001711279-26-000043.md) | [119](/filings/0001711279-26-000057.md) |
| Research and development | $m | [10.6](/filings/0001711279-24-000056.md) | [11.4 d](/filings/0001711279-26-000016.md) | [11.0](/filings/0001711279-25-000044.md) | [15.6](/filings/0001711279-25-000077.md) | [13.5](/filings/0001711279-25-000087.md) | [13.5 d](/filings/0001711279-26-000016.md) | [14.3](/filings/0001711279-26-000043.md) | [14.4](/filings/0001711279-26-000057.md) | [14.6](/filings/0001711279-25-000087.md) | [14.8 d](/filings/0001711279-26-000016.md) | [15.3](/filings/0001711279-26-000043.md) | [14.5](/filings/0001711279-26-000057.md) |
| Selling, general and administrative | $m | [23.7](/filings/0001711279-24-000056.md) | [24.7 d](/filings/0001711279-26-000016.md) | [26.1](/filings/0001711279-25-000044.md) | [27.6](/filings/0001711279-25-000077.md) | [28.7](/filings/0001711279-25-000087.md) | [31.3 d](/filings/0001711279-26-000016.md) | [32.6](/filings/0001711279-26-000043.md) | [35.1](/filings/0001711279-26-000057.md) | [37.6](/filings/0001711279-25-000087.md) | [41.4 d](/filings/0001711279-26-000016.md) | [41.0](/filings/0001711279-26-000043.md) | [39.9](/filings/0001711279-26-000057.md) |
| Operating income | $m | [(26.0)](/filings/0001711279-24-000056.md) | [3.2 d](/filings/0001711279-26-000016.md) | [(6.7)](/filings/0001711279-25-000044.md) | [8.6](/filings/0001711279-25-000077.md) | [22.5](/filings/0001711279-25-000087.md) | [41.4 d](/filings/0001711279-26-000016.md) | [36.3](/filings/0001711279-26-000043.md) | [39.4](/filings/0001711279-26-000057.md) | [41.4](/filings/0001711279-25-000087.md) | [44.3 d](/filings/0001711279-26-000016.md) | [53.7](/filings/0001711279-26-000043.md) | [58.4](/filings/0001711279-26-000057.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [0.0](/filings/0001711279-24-000056.md) | [2.0 d](/filings/0001711279-26-000016.md) | [0.0](/filings/0001711279-25-000044.md) | [0.5](/filings/0001711279-25-000077.md) | [2.6](/filings/0001711279-25-000087.md) | [3.1 d](/filings/0001711279-26-000016.md) | [7.9](/filings/0001711279-26-000043.md) | [8.4](/filings/0001711279-26-000057.md) | [(31.4)](/filings/0001711279-25-000087.md) | [(0.3) d](/filings/0001711279-26-000016.md) | [5.5](/filings/0001711279-26-000043.md) | [11.3](/filings/0001711279-26-000057.md) |
| Net income | $m | [80.7](/filings/0001711279-24-000056.md) | [8.7 d](/filings/0001711279-26-000016.md) | [0.9](/filings/0001711279-25-000087.md) | [15.6](/filings/0001711279-25-000087.md) | [27.2](/filings/0001711279-25-000087.md) | [45.5 d](/filings/0001711279-26-000016.md) | [35.7](/filings/0001711279-26-000057.md) | [38.3](/filings/0001711279-26-000057.md) | [79.4](/filings/0001711279-25-000087.md) | [51.4 d](/filings/0001711279-26-000016.md) | [55.9](/filings/0001711279-26-000057.md) | [54.8](/filings/0001711279-26-000057.md) |
| Diluted EPS | $ per share | [2.79](/filings/0001711279-24-000056.md) | not reported | [0.03](/filings/0001711279-25-000044.md) | [0.53](/filings/0001711279-25-000077.md) | [0.91](/filings/0001711279-25-000087.md) | not reported | [1.20](/filings/0001711279-26-000043.md) | [1.29](/filings/0001711279-26-000057.md) | [2.66](/filings/0001711279-25-000087.md) | not reported | [1.83](/filings/0001711279-26-000043.md) | [1.79](/filings/0001711279-26-000057.md) |
| Basic EPS | $ per share | [2.88](/filings/0001711279-24-000056.md) | not reported | [0.03](/filings/0001711279-25-000044.md) | [0.54](/filings/0001711279-25-000077.md) | [0.95](/filings/0001711279-25-000087.md) | not reported | [1.24](/filings/0001711279-26-000043.md) | [1.33](/filings/0001711279-26-000057.md) | [2.74](/filings/0001711279-25-000087.md) | not reported | [1.91](/filings/0001711279-26-000043.md) | [1.85](/filings/0001711279-26-000057.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [373](/filings/0001711279-23-000073.md) | [358](/filings/0001711279-25-000008.md) | [359](/filings/0001711279-24-000020.md) | [346](/filings/0001711279-24-000040.md) | [374](/filings/0001711279-24-000056.md) | [345](/filings/0001711279-26-000016.md) | [309](/filings/0001711279-25-000044.md) | [354](/filings/0001711279-25-000077.md) | [393](/filings/0001711279-25-000087.md) | [496](/filings/0001711279-26-000057.md) | [501](/filings/0001711279-26-000043.md) | [428](/filings/0001711279-26-000057.md) |
| Current assets | $m | [582](/filings/0001711279-23-000073.md) | [588](/filings/0001711279-25-000008.md) | [602](/filings/0001711279-24-000020.md) | [683](/filings/0001711279-24-000040.md) | [713](/filings/0001711279-24-000056.md) | [742](/filings/0001711279-26-000016.md) | [767](/filings/0001711279-25-000044.md) | [841](/filings/0001711279-25-000077.md) | [926](/filings/0001711279-25-000087.md) | [1,025](/filings/0001711279-26-000057.md) | [1,020](/filings/0001711279-26-000043.md) | [1,060](/filings/0001711279-26-000057.md) |
| Total assets | $m | [790](/filings/0001711279-23-000073.md) | [818](/filings/0001711279-25-000008.md) | [853](/filings/0001711279-24-000020.md) | [918](/filings/0001711279-24-000040.md) | [982](/filings/0001711279-24-000056.md) | [1,056](/filings/0001711279-26-000016.md) | [1,074](/filings/0001711279-25-000044.md) | [1,138](/filings/0001711279-25-000077.md) | [1,240](/filings/0001711279-25-000087.md) | [1,334](/filings/0001711279-26-000057.md) | [1,397](/filings/0001711279-26-000043.md) | [1,501](/filings/0001711279-26-000057.md) |
| Current liabilities | $m | [27.6](/filings/0001711279-23-000073.md) | [33.1](/filings/0001711279-25-000008.md) | [47.6](/filings/0001711279-24-000020.md) | [71.9](/filings/0001711279-24-000040.md) | [89.5](/filings/0001711279-24-000056.md) | [102](/filings/0001711279-26-000016.md) | [79.5](/filings/0001711279-25-000044.md) | [86.9](/filings/0001711279-25-000077.md) | [91.3](/filings/0001711279-25-000087.md) | [103](/filings/0001711279-26-000057.md) | [108](/filings/0001711279-26-000043.md) | [127](/filings/0001711279-26-000057.md) |
| Total liabilities | $m | [34.4](/filings/0001711279-23-000073.md) | [39.7](/filings/0001711279-25-000008.md) | [54.1](/filings/0001711279-24-000020.md) | [78.8](/filings/0001711279-24-000040.md) | [96.5](/filings/0001711279-24-000056.md) | [109](/filings/0001711279-26-000016.md) | [89.7](/filings/0001711279-25-000044.md) | [97.7](/filings/0001711279-25-000077.md) | [102](/filings/0001711279-25-000087.md) | [114](/filings/0001711279-26-000057.md) | [120](/filings/0001711279-26-000043.md) | [142](/filings/0001711279-26-000057.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [756](/filings/0001711279-24-000056.md) | [779](/filings/0001711279-26-000016.md) | [799](/filings/0001711279-25-000087.md) | [839](/filings/0001711279-25-000087.md) | [886](/filings/0001711279-25-000087.md) | [946](/filings/0001711279-26-000057.md) | [985](/filings/0001711279-26-000057.md) | [1,041](/filings/0001711279-26-000057.md) | [1,138](/filings/0001711279-25-000087.md) | [1,220](/filings/0001711279-26-000057.md) | [1,277](/filings/0001711279-26-000057.md) | [1,359](/filings/0001711279-26-000057.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(21.2) d](/filings/0001711279-24-000056.md) | [(7.2) d](/filings/0001711279-26-000016.md) | [15.9](/filings/0001711279-25-000044.md) | [(4.2) d](/filings/0001711279-25-000077.md) | [58.9 d](/filings/0001711279-25-000087.md) | [52.8 d](/filings/0001711279-26-000016.md) | [31.0](/filings/0001711279-26-000043.md) | [52.7 d](/filings/0001711279-26-000057.md) | [39.7 d](/filings/0001711279-25-000087.md) | [77.5 d](/filings/0001711279-26-000016.md) | [80.4](/filings/0001711279-26-000043.md) | [74.8 d](/filings/0001711279-26-000057.md) |
| Capital expenditure | $m | [1.8 d](/filings/0001711279-24-000056.md) | [1.8 d](/filings/0001711279-26-000016.md) | [1.3](/filings/0001711279-25-000044.md) | [1.1 d](/filings/0001711279-25-000077.md) | [1.0 d](/filings/0001711279-25-000087.md) | [0.8 d](/filings/0001711279-26-000016.md) | [6.2](/filings/0001711279-26-000043.md) | [1.9 d](/filings/0001711279-26-000057.md) | [1.7 d](/filings/0001711279-25-000087.md) | [2.1 d](/filings/0001711279-26-000016.md) | [7.1](/filings/0001711279-26-000043.md) | [3.6 d](/filings/0001711279-26-000057.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q1 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [25.6](/filings/0001711279-23-000073.md) | [25.7](/filings/0001711279-24-000020.md) | [26.7](/filings/0001711279-24-000040.md) | [28.9](/filings/0001711279-24-000056.md) | [29.3](/filings/0001711279-25-000044.md) | [29.6](/filings/0001711279-25-000077.md) | [29.9](/filings/0001711279-25-000087.md) | [29.9](/filings/0001711279-26-000043.md) | [29.7](/filings/0001711279-26-000057.md) | [29.8](/filings/0001711279-25-000087.md) | [30.5](/filings/0001711279-26-000043.md) | [30.7](/filings/0001711279-26-000057.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 29,598,836 at 2026-07-28, from the cover of the [10-Q filed 2026-08-03](/filings/0001711279-26-000057.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:46 ET. No prices; not investment advice.